Swiss drug giant Novartis is ending its trial of malaria drug hydroxychloroquine against Covid-19 after failing to find enough participants, it said on Friday.
This content was published on
2 minutes
Keystone-SDA/Reuters/sb
Basel-based Novartis began the clinical trial in April. Some 440 hospitalised patients with the virus were expected to participate in the study.
But the pharma company said on June 19External link that it had decided to halt the trial due to “acute enrolment challenges that have made trial completion infeasible”.
Novartis’ move follows this week’s US Food and Drug Administration’s (FDA) decision to revoke emergency use authorisation for hydroxychloroquine against Covid-19 on grounds it and a related drug, chloroquine, are unlikely to help patients.
Hydroxychloroquine, also used to treat inflammatory disorders including rheumatoid arthritis and lupus, has been caught in a political debate as US President Donald Trump promoted it, even though there was no scientific evidence that it helps against the new coronavirus.
Several studies of the decades-old malaria drug including in Britain were recently halted after scientists concluded it was “useless” against COVID-19. Last week the World Health Organization halted the hydroxychloroquine arm of one of its trials.
“The recruitment challenge facing our hydroxychloroquine trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable time frame to determine the efficacy of hydroxychloroquine in treating patients with COVID-19,” Novartis said.
The pharmaceutical company said its study, so far, raised no safety issues and drew no conclusions about hydroxychloroquine’s efficacy.
Novartis had donated up to 130 million doses of hydroxychloroquine, including millions in the United States, and Chief Executive Vas Narasimhan two months ago claimed the drug was the company’s biggest hope against the new coronavirus.
Swiss centre records over 200 victims of human trafficking
This content was published on
Last year 317 people took part in a protection programme run by the Specialist Unit for Trafficking in Women and Women’s Migration (FIZ) in German-speaking Switzerland.
This content was published on
The Geneva-based International Committee of the Red Cross (ICRC) and partners are opening a field hospital in southern Gaza on Tuesday.
Lack of smartphone sustainability in Switzerland hits environment
This content was published on
Almost half of all Swiss citizens hang on to their old smartphones, tablets and laptops, according to the Federal Statistical Office.
Police clear out pro-Palestinian students protesting in Geneva
This content was published on
The police intervened early on Tuesday to dislodge pro-Palestinian students who had been occupying the University of Geneva for almost a week.
New gel developed in Zurich renders alcohol harmless
This content was published on
A newly developed gel composed of whey proteins breaks down alcohol in the body and could reduce its harmful and intoxicating effects in humans.
Pro-Palestine protests extend to Basel and Fribourg universities
This content was published on
Demonstrators called for an academic boycott of all Israeli institutions and disassociation with Chaim Weizmann, the first Israeli president.
This content was published on
In many cases, China's use of AI undermines the national security of the US and its allies, according to a US government representative.
Swiss Hells Angels trial alleges rape and money laundering
This content was published on
An allegedly high-ranking member of the Hells Angels is accused of money laundering totalling millions and rape, among other serious crimes.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 is both threat and opportunity for Swiss biotech
This content was published on
Although the coronavirus pandemic is the Swiss biotech industry’s time to shine, it has left many smaller firms struggling to survive.
Hydroxychloroquine study withdrawn over data concerns
This content was published on
Authors have withdrawn an influential article finding that hydroxychloroquine had no benefit against Covid-19, citing data concerns.
Novartis CEO warns that data on Covid-19 drugs is missing
This content was published on
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.